Honasa buys 58% of Fluence Pharma for ₹135 Cr, enters nutraceuticals via Honasa Health

Mamaearth parent acquires majority in Fluence Pharma (FY25 revenue ₹37.2 Cr), launching subsidiary Honasa Health to crack the ₹16,000 Cr Indian nutraceuticals market. Move backs Honasa 3.0 plan targeting ₹5,500 Cr revenue by FY31, with remaining 42% to be picked up over 5-7 years.

— Source publishedTue, 23 Jun, 2026, 21:11 IST·First seen Tue, 23 Jun, 2026, 21:13 IST·Source Inc42 · Buzz

What happened

Honasa Consumer acquires 58% of nutraceuticals firm Fluence Pharma for ₹135 Cr, entering supplements via new subsidiary Honasa Health. Move aligns with Honasa

Key facts

  • ₹135 Cr deal
  • 58% stake
  • 42% remainder over 5-7 years
  • Fluence FY25 revenue ₹37.2 Cr
  • 3,000+ dermatologists network
  • India nutraceuticals market ₹16,000 Cr
  • Honasa FY26 net profit ₹200.2 Cr (+175.4%)
  • FY26 revenue ₹2,391.9 Cr (+15.7%)
  • FY31 revenue target ₹5,500 Cr
  • offline outlets 1.2L to 3L+

Why this matters

Phased 58% now + 42% over 5-7 years is the template to watch — majority control with founder alignment lets Honasa absorb regulatory and formulation IP before full consolidation.

Also reported by